Insights into pharmacogenomics and its impact upon immunosuppressive therapy

Yoram Yagil, Chana Yagil

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


The advent of the genomic era has brought about several new fields of study, one of them being pharmacogenomics, which seeks to link drug treatment (pharmaco-) with the individual's genetic make-up (genomics). Pharmacogenomics holds many promises for improved treatment of a large variety of medical conditions, including immunosuppression for organ transplantation and autoimmune disease. Many of these promises have, however, not yet been fulfilled. In this brief overview of the subject, we attempt to provide insights into the evolving field of pharmacogenomics and discuss some of its potential benefits and promises, technological tools used by pharmacogenomics, the reasons for delays in breakthroughs in the field, and the relevance of pharmacogenomics to immunosuppression.

Original languageEnglish
Pages (from-to)203-209
Number of pages7
JournalTransplant Immunology
Issue number2-4
StatePublished - 1 May 2002


  • DNA microarrays
  • Differential gene expression
  • Drugs
  • Efficacy
  • Genes
  • Genome
  • Pharmacogenetics
  • Pharmacogenomics
  • Side effects
  • Single-nucleotide polymorphisms (SNPs)
  • Tolerability
  • Toxicity

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Transplantation


Dive into the research topics of 'Insights into pharmacogenomics and its impact upon immunosuppressive therapy'. Together they form a unique fingerprint.

Cite this